Biochemical Engineering Special Interest Group
biological engineering professionals
30 June 2016

BMS partners with British biotech for late-stage cancer combo trials with Opdivo

Bristol-Myers Squibb ($BMY) and PsiOxus Therapeutics have partnered to put a pair of candidates into Phase I testing to treat several tumor types in late-stage cancer patients. The testing will combine the biopharma’s FDA-approved immuno-oncology agent Opdivo (nivolumab) with PsiOxus’ enadenotucirev, an oncolytic adenovirus. Source: FierceBiotech 30/6/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).